| 摘要 |
A raloxifene derivative of formula I or a pharmaceutically acceptable salt or solvate thereof and a progestin or a pharmaceutically acceptable salt thereof are used in a manufacture of a medicament for treating osteoporosis, for retaining or increasing bone density or inhibiting bone loss. In formula I: R and R1 are H, OH, alkoxy, acyloxy, alkoxy-acyloxy, R2-substituted aryloxy, R2-substituted aroyloxy, R3-substituted carbonyloxy or halo; R2 is alkyl, alkoxy, H or halo; R3 is alkoxy or aryloxy; n is 2 to 4 and p is 4 to 6. The progestin is medroxyprogestrone, norethindrone or norethynodrel.
|
